I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 743886065 US, in an envelope addressed to: MS PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: July 25, 2006

Patent

Docket No. 397272001500

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Vladimir SLEPUSHKIN et al.

Application No.: Not Yet Assigned

Filed: Concurrently Herewith

International Application No.: PCT/US2006/019709

Confirmation No.: N/A

International Filing Date: May 22, 2006

Art Unit: Not Yet Assigned

For: TRANSDUCTION OF PRIMARY CELLS

Examiner: Not Yet Assigned

### INFORMATION DISCLOSURE **STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98**

MS PCT Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. Copies of foreign documents and non-patent literature are submitted herewith. The Examiner is requested to make these documents of record.

This Information Disclosure Statement is submitted:

$\boxtimes$	With the application; accordingly, no fee or separate requirements are required.
	Before the mailing of a first Office Action after the filing of a Request for Continued
	Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97
	(e)(1) has been provided.

Ш	Withi	n three months of the application filing date or before mailing of a first Office Action
	on the	merits; accordingly, no fee or separate requirements are required. However, if
	applic	able, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
	After	receipt of a first Office Action on the merits but before mailing of a final Office Action
	or No	tice of Allowance.
		A fee is required. A check in the amount of is enclosed.
		A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to
		this submission in duplicate.
		A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee is
		believed to be due.
	After	mailing of a final Office Action or Notice of Allowance, but before payment of the
	issue	fee.
		A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the
		amount of is enclosed.
		A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal
		form (PTO/SB/17 is attached to this submission in duplicate.)

Applicants would appreciate the Examiner initialing and returning the Form PTO/SB/08a/b, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petition and/or other

# SAP20 Rec'd FCT/PTO 25 JUL 2006

fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing (397272001500).

Dated: July 25, 2006

Respectfully submitted,

By Brenda J. Wallach

Registration No.: 45,193

MORRISON & FOERSTER LLP

12531 High Bluff Drive

Suite 100

San Diego, California 92130-2040

(858) 720-7961

## ¡AP20 Rec'd PCT/PTO 25 JUL 2006

ALTERNATIVE TO PTO/SB/08a/b (07-05)

S1	ostitute for form 1449/PTO			Complete if Known		
Suc	ostitute for form 1449/P10			Application Number	Not Yet Assigned 3/43/	
11	NFORMATION	l DI	SCLOSURE	Filing Date	Concurrently Herewith	
1	STATEMENT BY APPLICANT			First Named Inventor	Vladimir SLEPUSHKIN	
		· ·		Art Unit	Not Yet Assigned	
	(Use as many sheets as necessary)			Examiner Name	Not Yet Assigned	
Sheet	1	of	2	Attorney Docket Number	397272001500	

	U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where			
		Number-Kind Code <sup>2</sup> (if known)		Applicant of Cited Document	Relevant Passages or Relevant Figures Appear			
	1.	US-5,512,421	04/1996	Burns et al.				
	2.	US-5,739,018	04/1998	Miyanohara et al.				
	3.	US-5,814,500	09/1998	Dietx				
	4.	US-5,885,806	03/1999	Dropulic et al.				
	5.	US-6,013,516	01/2000	Verma et al.				
	6.	US-6,060,317	05/2000	Malech				
	7.	US-6,627,442	09/2003	Humeau et al.				

	FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Foreign Patent Document  Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>			
	8.	WO-96/34970	11-07-1996	June et al.					
	9.	WO-02/18609	03-07-2002	Humeau et al.					

\*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	10.	ANDERSON, Nature (1998) 392:25-28	
	11.	BARRY et al., Human Gene Therapy (2000) 11:323-332	
	12.	CHINNASAMY et al., Blood (2000) 96(4):1309-1316	
	13.	COSTELLO et al., Gene Therapy (2000) 7:596-604	
	14.	DOUGLAS et al., Human Gene Therapy (1999) 10:935-945	
	15.	FOLLENZI et al., Nature Genetics (2000) 25:217-222	
	16.	HAN et al., Blood (2000) 95:1616-1625	
	17.	HAAS et al., Molecular Therapy (2000) 2:71-80	
	18.	HOOIJBERG et al., Blood 92000) 96:459-466	
	19.	KLEBBA et al., Gene Therapy (2000) 7:408-416	
	20.	KLEIN et al., Gene Therapy (2000) 7:458-463	
	21.	MADDENS et al., Journal of Hematotherapy & Stem Cell Research (2000) 9:225-236	
	22.	MITROPHANOUS et al., Gene Therapy (1999) 6:1808-1818	
	23.	MOVASSAGH et al., Human Gene Therapy (2000) 11:1189-1200	
	24.	MOVASSAGH et al., Human Gene Therapy (1999) 10(2):175-187	
	25.	NALDINI et al., Science (1996) 272:263-267	
	26.	ONODERA et al., Blood (1998) 91:30-36	

Examiner	Date	
Signature	Considered	
1 00700	 	·

sd- 327397

### ;AP20 Rec'd PCT/PTO 25 JUL 2006

ALTERNATIVE TO PTO/SB/08a/b (07-05)

Coloridate for form 4440/DTO		Complete if Known			
Substitute for form 1449/PTO				Application Number	Not Ye Assigned 7 437
IN	IFORMATIO	N DI	SCLOSURE	Filing Date	Concurrently Herewith
STATEMENT BY APPLICANT				First Named Inventor	Vladimir SLEPUSHKIN
O	STATEMENT BY AFFEIGANT		Art Unit	Not Yet Assigned	
(Use as many sheets as necessary)		Examiner Name	Not Yet Assigned		
Sheet	2	of	2	Attorney Docket Number	397272001500

27.	QUINN et al., Human Gene Therapy (1998) 9(10):1457-1467	
28.	RICHARDSON et al., Gene Therapy (1998) 5:635-644	
29.	ST. CROIX et al., Science (2000) 289:1197-1202	
30.	STULL et al., Cytometry (2000) 40:126-134	
31.	TAKAYAMA et al., Gene Therapy (2000) 7:1265-1273	
32.	UCHIDA et al., PNAS USA (1998) 95(20):11939-11944	
33.	UNUTMAZ et al., J. Exp. Med. (1999) 11:1735-1746	
34.	ZENNOU et al., Cell (2000) 101:173-185	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	Date	
Signature	Considered	- 1

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.